Workflow
Earnings outlook
icon
Search documents
Lincoln National (LNC) Surpasses Q3 Earnings Estimates
ZACKS· 2025-10-30 12:16
Core Insights - Lincoln National (LNC) reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $1.84 per share, but slightly down from $2.06 per share a year ago, resulting in an earnings surprise of +10.87% [1] - The company posted revenues of $4.78 billion for the quarter ended September 2025, missing the Zacks Consensus Estimate by 0.45%, compared to $4.6 billion in the same quarter last year [2] - Lincoln National shares have increased by approximately 26.2% year-to-date, outperforming the S&P 500's gain of 17.2% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.90 on revenues of $4.86 billion, and for the current fiscal year, it is $7.72 on revenues of $19.07 billion [7] - The estimate revisions trend for Lincoln National was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Insurance - Life Insurance industry, to which Lincoln National belongs, is currently in the top 30% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Primerica (PRI), is expected to report quarterly earnings of $5.51 per share, reflecting a year-over-year decline of 3%, with revenues projected at $825.51 million, up 7.2% from the previous year [9][10]
JetBlue Airways (JBLU) Reports Q3 Loss, Misses Revenue Estimates
ZACKS· 2025-10-28 13:11
Core Insights - JetBlue Airways reported a quarterly loss of $0.4 per share, which was better than the Zacks Consensus Estimate of a loss of $0.43, representing an earnings surprise of +6.98% [1] - The company posted revenues of $2.32 billion for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.12% and down from $2.37 billion a year ago [2] - JetBlue shares have declined approximately 40% year-to-date, contrasting with the S&P 500's gain of 16.9% [3] Financial Performance - Over the last four quarters, JetBlue has surpassed consensus EPS estimates four times and topped revenue estimates twice [2] - The current consensus EPS estimate for the upcoming quarter is -$0.37 on revenues of $2.26 billion, and for the current fiscal year, it is -$1.60 on revenues of $9.08 billion [7] Market Outlook - The sustainability of JetBlue's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for JetBlue is currently 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [6] - The Transportation - Airline industry is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]
Enova International (ENVA) Q3 Earnings Top Estimates
ZACKS· 2025-10-23 22:31
Core Insights - Enova International (ENVA) reported quarterly earnings of $3.36 per share, exceeding the Zacks Consensus Estimate of $3.05 per share, and showing an increase from $2.45 per share a year ago, resulting in an earnings surprise of +10.16% [1] - The company posted revenues of $802.68 million for the quarter ended September 2025, which was slightly below the Zacks Consensus Estimate by 0.83%, but an increase from $689.92 million year-over-year [2] - Enova International's stock has increased approximately 18.9% since the beginning of the year, outperforming the S&P 500's gain of 13.9% [3] Earnings Outlook - The future performance of Enova International's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $2.98, with expected revenues of $854.73 million, and for the current fiscal year, the EPS estimate is $12.16 on revenues of $3.17 billion [7] Industry Context - The Financial - Consumer Loans industry, to which Enova International belongs, is currently ranked in the top 40% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The performance of Enova International's stock may also be influenced by the overall industry outlook, as empirical research shows a strong correlation between stock movements and earnings estimate revisions [5][8]
Reliance (RS) Lags Q3 Earnings Estimates
ZACKS· 2025-10-22 22:26
Reliance (RS) came out with quarterly earnings of $3.64 per share, missing the Zacks Consensus Estimate of $3.68 per share. This compares to earnings of $3.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -1.09%. A quarter ago, it was expected that this metals service-center company would post earnings of $4.72 per share when it actually produced earnings of $4.43, delivering a surprise of -6.14%.Over the last four quarters, ...
Constellation Brands, Inc. (NYSE:STZ) Earnings Outlook and Financial Challenges
Financial Modeling Prep· 2025-09-30 09:00
Core Insights - Constellation Brands, Inc. is facing significant challenges, including a 37% stock decline this year, contrasting with the S&P 500's 12% rise [1] - The company is set to release its quarterly earnings on October 6, 2025, with analysts predicting an EPS of $3.37 and revenue of approximately $2.48 billion, but a decline in earnings is expected for the quarter ending August 2025 [2][6] - Changing consumer habits, particularly among younger demographics, are impacting beer consumption, contributing to the company's financial challenges [4][6] Financial Metrics - Constellation Brands has a price-to-sales ratio of about 2.39, indicating investors are willing to pay $2.39 for every dollar of sales [5] - The enterprise value to sales ratio is approximately 3.53, and the enterprise value to operating cash flow ratio is around 11.47 [5] - The company's debt-to-equity ratio stands at about 1.59, suggesting a higher level of debt compared to equity [5][6] Market Impact - The upcoming earnings report could significantly impact STZ's stock price, with potential for a rise if expectations are exceeded, or a decline if they are not met [3]
Nucor Stock Dives After Steelmaker Cuts Q3 Earnings Outlook
Benzinga· 2025-09-17 21:32
Company Overview - Nucor Corp (NUE) shares are experiencing a decline in after-hours trading following the release of soft guidance for the third quarter, with expected earnings between $2.05 to $2.15 per share, significantly lower than the estimated $2.61 per share [1][2]. Earnings Forecast - The company anticipates a decrease in earnings across all three operating segments for the third quarter of 2025 compared to the second quarter of 2025. Steel mill earnings are expected to decline due to lower volumes and margin compression, while steel products earnings will decrease due to higher average costs per ton despite stable pricing and volumes. Additionally, raw material earnings are projected to fall due to reduced profitability in scrap processing operations [2]. Market Sentiment - Wall Street analysts generally view Nucor as a Buy, with Christopher LeFemina from Jefferies predicting a 25.93% increase in stock price over the next year [4]. - Over the past three months, Nucor's stock has risen by 10.56%, indicating improved investor sentiment regarding the company's attractiveness based on stock price and underlying fundamentals, including a 4.69% increase in revenue over the past year [5]. Stock Performance - As of the latest update, Nucor shares were down 5.11% in after-hours trading, priced at $135.50 [6]. - The company is scheduled to release its third-quarter financial results after market close on October 27 [3].
Synchronoss (SNCR) Q2 Earnings and Revenues Miss Estimates
ZACKS· 2025-08-12 00:06
Core Insights - Synchronoss (SNCR) reported quarterly earnings of $0.1 per share, missing the Zacks Consensus Estimate of $0.25 per share, and down from $0.48 per share a year ago, indicating a -60.00% earnings surprise [1] - The company posted revenues of $42.49 million for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.24%, and down from $43.46 million year-over-year [2] - Synchronoss shares have declined approximately 18.5% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $42.96 million, and for the current fiscal year, it is $1.17 on revenues of $172.42 million [7] - The estimate revisions trend for Synchronoss was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Internet - Software industry, to which Synchronoss belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting that companies in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - Another company in the same industry, KORE Group Holdings, is expected to report a quarterly loss of $0.47 per share, reflecting a year-over-year change of +52.5%, with revenues anticipated at $70.3 million, up 3.6% from the previous year [9][10]
Roivant Sciences Ltd. (ROIV) Reports Q1 Loss, Misses Revenue Estimates
ZACKS· 2025-08-11 13:16
分组1 - Roivant Sciences Ltd. reported a quarterly loss of $0.18 per share, better than the Zacks Consensus Estimate of a loss of $0.23, representing an earnings surprise of +21.74% [1] - Montes Archimedes Acquisition posted revenues of $2.17 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 71.42%, compared to year-ago revenues of $55.13 million [2] - The stock of Montes Archimedes Acquisition has underperformed, losing about 2.9% since the beginning of the year, while the S&P 500 gained 8.6% [3] 分组2 - The current consensus EPS estimate for Montes Archimedes Acquisition is -$0.25 on revenues of $7.59 million for the coming quarter and -$1.01 on revenues of $28.53 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 41% of over 250 Zacks industries, indicating potential underperformance compared to the top 50% [8] - Adherex Technologies Inc., another company in the same industry, is expected to report a quarterly loss of $0.06 per share, with revenues projected at $9.49 million, reflecting a year-over-year increase of 30.7% [9]
Clean Energy Fuels (CLNE) Reports Break-Even Earnings for Q2
ZACKS· 2025-08-07 23:06
Financial Performance - Clean Energy Fuels reported break-even quarterly earnings per share, compared to a Zacks Consensus Estimate of a loss of $0.07, and earnings of $0.01 per share a year ago [1] - The quarterly report represents an earnings surprise of +100.00%, with a previous expectation of a loss of $0.20 per share, resulting in a surprise of +105% [2] - The company posted revenues of $102.61 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 14.93%, compared to year-ago revenues of $97.95 million [3] Market Performance - Clean Energy Fuels shares have lost about 19.1% since the beginning of the year, while the S&P 500 has gained 7.9% [4] - The current consensus EPS estimate for the coming quarter is -$0.06 on revenues of $92.03 million, and -$0.15 on revenues of $381.4 million for the current fiscal year [8] Industry Outlook - The Utility - Gas Distribution industry, to which Clean Energy Fuels belongs, is currently in the top 20% of over 250 Zacks industries, indicating a favorable outlook [9]
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates
ZACKS· 2025-08-07 13:21
Company Performance - Insmed reported a quarterly loss of $1.7 per share, which was worse than the Zacks Consensus Estimate of a loss of $1.3, and an improvement from a loss of $1.94 per share a year ago [1][2] - The earnings surprise for this quarter was -30.77%, and the company has not surpassed consensus EPS estimates over the last four quarters [2] - Insmed's revenues for the quarter ended June 2025 were $107.42 million, exceeding the Zacks Consensus Estimate by 3.87%, and up from $90.34 million year-over-year [3] Stock Performance - Insmed shares have increased approximately 61.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [4] - The current Zacks Rank for Insmed is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [7] Future Outlook - The consensus EPS estimate for the upcoming quarter is -$1.30 on revenues of $115.44 million, and for the current fiscal year, it is -$5.29 on revenues of $464.32 million [8] - The outlook for the Medical - Biomedical and Genetics industry, where Insmed operates, is currently in the top 41% of over 250 Zacks industries, suggesting a favorable environment for stock performance [9]